Chongqing Genrix Biopharmaceutical Co. Ltd. A

Fosun Pharma announced that its controlling subsidiary Yaopharma and Genrix Bio signed a licensing agreement granting rights to the GR1803 injection, which has received conditional approval for market launch from the National Medical Products Administration. The drug is a bispecific antibody targeting both BCMA and CD3, capable of redirecting cytotoxic T cells to cells expressing BCMA. The approved indication is for adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy.

Genrix Bio announced that its investigational product GR2302 injection has received approval for its clinical trial application. GR2302 injection is a bispecific antibody independently developed by the company, based on a TCR-mimic antibody and an anti-CD3 antibody. As of the announcement date, no drugs targeting the same target have been approved for clinical trials in China. In the first quarter of 2026, Genrix Bio achieved revenue of 67.25 million yuan and a net loss attributable to the parent company of 149 million yuan.

China’s National Medical Products Administration has approved Silevimig Injection, a Class 1 therapeutic biological product from China Medical System Holdings, for passive immunization in adults following rabies virus exposure. The drug is the world’s first fully human bispecific antibody targeting dual epitopes of the rabies virus, consistent with WHO recommendations for a cocktail therapeutic paradigm. It demonstrated non-inferior protective efficacy compared with human rabies immune globulin in a Phase III trial and is the smallest-dose passive immunization product for rabies, reducing injection volume and patient pain. The approval expands CMS’s commercialized innovative drug portfolio to eight products, with six more under marketing review and about 20 in clinical development. CMS holds exclusive commercialization rights in mainland China and exclusive licensing rights for the rest of Asia-Pacific, the Middle East, and North Africa under a 2025 agreement with Chongqing Genrix Biopharmaceutical.